Human monoclonal antibodies against oxidized ldl receptor and medicinal use thereof
OwnerYuko Kobayashi, Hiroyuki Tsuji +2inventors
InventorsYuko Kobayashi, Hiroyuki Tsuji, Masafumi Kamada, Tatsuya Sawamura
Life of this patent
Estimating the term…
Abstract
Various human monoclonal antibodies that bind to human LOX-1 and inhibit the binding of in-vivo LOX-1 ligands to LOX-1, and the LOX-1-mediated incorporation of the ligands into cells, were obtained by immunizing human antibody-producing transgenic mice (created by genetic engineering) with soluble human oxidized LDL receptor (LOX-1). Furthermore, the human monoclonal antibodies were found to be effective in preventing and treating a variety of diseases.
Claims30
A human monoclonal antibody, or a portion thereof, which binds to the human oxidized LDL receptor.
A pharmaceutical composition for suppressing or preventing thrombus formation, wherein the pharmaceutical composition comprises a substance that has the activity of inhibiting the binding of an in-vivo ligand of human oxidized LDL receptor, or the incorporation of the ligand into cells expressing the oxidized LDL receptor.
Dependencies are inferred from the claim text.